Shlush LI, Mitchell A. AML evolution from preleukemia to leukemia and relapse. Best Pract Res Clin Haematol. 2015;28(2–3):81–9.

Article  PubMed  Google Scholar 

Yang L, Rau R, Goodell MA. DNMT3A in haematological malignancies. Nat Rev Cancer. 2015;15(3):152–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, Kandoth C, Payton JE, Baty J, Welch J, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363(25):2424–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang L, Rodriguez B, Mayle A, Park HJ, Lin X, Luo M, Jeong M, Curry CV, Kim SB, Ruau D, et al. DNMT3A loss drives enhancer hypomethylation in FLT3-ITD-associated leukemias. Cancer Cell. 2016;29(6):922–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marcucci G, Metzeler KH, Schwind S, Becker H, Maharry K, Mrozek K, Radmacher MD, Kohlschmidt J, Nicolet D, Whitman SP, et al. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol. 2012;30(7):742–50.

Article  PubMed  PubMed Central  Google Scholar 

Thol F, Damm F, Ludeking A, Winschel C, Wagner K, Morgan M, Yun H, Gohring G, Schlegelberger B, Hoelzer D, et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol. 2011;29(21):2889–96.

Article  CAS  PubMed  Google Scholar 

Renneville A, Boissel N, Nibourel O, Berthon C, Helevaut N, Gardin C, Cayuela JM, Hayette S, Reman O, Contentin N, et al. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association. Leukemia. 2012;26(6):1247–54.

Article  CAS  PubMed  Google Scholar 

Ostronoff F, Othus M, Ho PA, Kutny M, Geraghty DE, Petersdorf SH, Godwin JE, Willman CL, Radich JP, Appelbaum FR, et al. Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report. Leukemia. 2013;27(1):238–41.

Article  CAS  PubMed  Google Scholar 

Xu Y, Sun Y, Shen H, Ding L, Yang Z, Qiu H, Sun A, Chen S, Wu D. Allogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloid leukemia patients with DNMT3A mutations. Am J Hematol. 2015;90(11):992–7.

Article  CAS  PubMed  Google Scholar 

Dohner H, Dolnik A, Tang L, Seymour JF, Minden MD, Stone RM, Del Castillo TB, Al-Ali HK, Santini V, Vyas P, et al. Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care. Leukemia. 2018;32(12):2546–57.

Article  PubMed  PubMed Central  Google Scholar 

Ayala R, Rapado I, Onecha E, Martinez-Cuadron D, Carreno-Tarragona G, Bergua JM, Vives S, Algarra JL, Tormo M, Martinez P, et al. The mutational landscape of acute myeloid leukaemia predicts responses and outcomes in elderly patients from the PETHEMA-FLUGAZA phase 3 clinical trial. Cancers. 2021;13(10):2458.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Luskin MR, Lee JW, Fernandez HF, Abdel-Wahab O, Bennett JM, Ketterling RP, Lazarus HM, Levine RL, Litzow MR, Paietta EM, et al. Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood. 2016;127(12):1551–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guryanova OA, Shank K, Spitzer B, Luciani L, Koche RP, Garrett-Bakelman FE, Ganzel C, Durham BH, Mohanty A, Hoermann G, et al. DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. Nat Med. 2016;22(12):1488–95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maral RJ, Jouanne M. Toxicology of daunorubicin in animals and man. Cancer Treat Rep. 1981;65(Suppl 4):9–18.

CAS  PubMed  Google Scholar 

Ma Q. Role of nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol. 2013;53:401–26.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shanmugam G, Narasimhan M, Tamowski S, Darley-Usmar V, Rajasekaran NS. Constitutive activation of Nrf2 induces a stable reductive state in the mouse myocardium. Redox Biol. 2017;12:937–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Knatko EV, Ibbotson SH, Zhang Y, Higgins M, Fahey JW, Talalay P, Dawe RS, Ferguson J, Huang JT, Clarke R, et al. Nrf2 activation protects against solar-simulated ultraviolet radiation in mice and humans. Cancer Prev Res. 2015;8(6):475–86.

Article  CAS  Google Scholar 

Sekhar KR, Freeman ML. Nrf2 promotes survival following exposure to ionizing radiation. Free Radic Biol Med. 2015;88(Pt B):268–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xue J, Yu C, Tang Y, Mo W, Tang Z, Sheng W, Jiao Y, Zhu W, Cao J. NF-E2-related factor 2 (Nrf2) ameliorates radiation-induced skin injury. Front Oncol. 2021;11:680058.

Article  PubMed  PubMed Central  Google Scholar 

Mohs A, Otto T, Schneider KM, Peltzer M, Boekschoten M, Holland CH, Hudert CA, Kalveram L, Wiegand S, Saez-Rodriguez J, et al. Hepatocyte-specific NRF2 activation controls fibrogenesis and carcinogenesis in steatohepatitis. J Hepatol. 2021;74(3):638–48.

Article  CAS  PubMed  Google Scholar 

Wolowczyk C, Neckmann U, Aure MR, Hall M, Johannessen B, Zhao S, Skotheim RI, Andersen SB, Zwiggelaar R, Steigedal TS, et al. NRF2 drives an oxidative stress response predictive of breast cancer. Free Radic Biol Med. 2022;184:170–84.

Article  CAS  PubMed  Google Scholar 

Lignitto L, LeBoeuf SE, Homer H, Jiang S, Askenazi M, Karakousi TR, Pass HI, Bhutkar AJ, Tsirigos A, Ueberheide B, et al. Nrf2 activation promotes lung cancer metastasis by inhibiting the degradation of Bach1. Cell. 2019;178(2):316–29.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang Q, Zhang ZY, Du H, Li SZ, Tu R, Jia YF, Zheng Z, Song XM, Du RL, Zhang XD. DUB3 deubiquitinates and stabilizes NRF2 in chemotherapy resistance of colorectal cancer. Cell Death Differ. 2019;26(11):2300–13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lister A, Nedjadi T, Kitteringham NR, Campbell F, Costello E, Lloyd B, Copple IM, Williams S, Owen A, Neoptolemos JP, et al. Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. Mol Cancer. 2011;10:37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ren D, Villeneuve NF, Jiang T, Wu T, Lau A, Toppin HA, Zhang DD. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc Natl Acad Sci U S A. 2011;108(4):1433–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu Y, Lu Y, Celiku O, Li A, Wu Q, Zhou Y, Yang C. Targeting IDH1-mutated malignancies with NRF2 blockade. J Natl Cancer Inst. 2019;111(10):1033–41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee JH, Mohan CD, Deivasigamani A, Jung YY, Rangappa S, Basappa S, Chinnathambi A, Alahmadi TA, Alharbi SA, Garg M, et al. Brusatol suppresses STAT3-driven metastasis by downregulating epithelial-mesenchymal transition in hepatocellular carcinoma. J Adv Res. 2020;26:83–94.

Article  PubMed  PubMed Central  Google Scholar 

Oh ET, Kim CW, Kim HG, Lee JS, Park HJ. Brusatol-mediated inhibition of c-Myc increases HIF-1alpha degradation and causes cell death in colorectal cancer under hypoxia. Theranostics. 2017;7(14):3415–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Y, Guo Y, Feng Z, Bergan R, Li B, Qin Y, Zhao L, Zhang Z, Shi M. Involvement of the PI3K/Akt/Nrf2 signaling pathway in resveratrol-mediated reversal of drug resistance in HL-60/ADR cells. Nutr Cancer. 2019;71(6):1007–18.

Article  CAS  PubMed  Google Scholar 

Karathedath S, Rajamani BM, Musheer Aalam SM, Abraham A, Varatharajan S, Krishnamurthy P, Mathews V, Velayudhan SR, Balasubramanian P. Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2. PLoS ONE. 2017;12(5):e0177227.

Article  PubMed  PubMed Central  Google Scholar 

Liu P, Ma D, Wang P, Pan C, Fang Q, Wang J. Nrf2 overexpression increases risk of high tumor mutation burden in acute myeloid leukemia by inhibiting MSH2. Cell Death Dis. 2021;12(1):20.

Article  PubMed  PubMed Central  Google Scholar 

Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, Long N, Schultz AR, Traer E, Abel M, et al. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018;562(7728):526–31.

Article  CAS  PubMed  PubMed Central